•  
  •  
  •  
  •  

2025-10-02 11:11:40

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Hero MotoCorp Ltd dispatches 687,220 units in September 2025
  • Synbiotics Ltd's Amphotericin B Manufacturing Facility receives USFDA approval
  • Veefin has successfully integrated CRIF's Strategy One BRE with our no-code Digital Lending Stack
  • Sentynl Therapeutics updates on its NDA for CUTX-101
  • Unimech Aerospace and Manufacturing Ltd experiences slowdown in revenue

Keywords Selected:  Study

Research

  • Non-Metro banking customers prioritize insurance and transparency while metro customers favour lifestyle perks: Ujjivan SFB Study
  • Godrej Interio's 'HomeScapes' Study reveals Indians want ‘Me-Time’ at home
  • Rising frauds propel demand for AI/ML strategies: Experian Study
  • 96% of MSMEs expect profits to rise in 2023, says NeoGrowth's MSME Business Confidence Study

Stock Report

  • THE LANCET Regional Health publishes Pivotal Phase 3 Clinical Study on Miqnaf®
  • CuraTeQ Biologics Pvt Ltd completes Phase 3 Clinical Study for Denosumab Biosimilar
  • AI and Digital Twins Set to Redefine Aerospace by 2035, reveals TCS Study
  • KP Group Featured in IBM Global Case Study on Scaling Clean Energy with Intelligent Asset Monitoring
  • Hexaware ranked First in General Satisfaction in Whitelane Study for Europe
  • 2025 to be the year of electric vehicles: 64% of Consumers Likely to Choose EV as Their Next Vehicle, reveals TCS global Study
  • Aurigene Oncology Ltd announces promising results of Phase 1 study for India's first trial for novel autologous CAR-T cell therapy for multiple myeloma
  • Suven Life Sciences to Present Positive Results from Phase-2a Proof-of-Concept Study of Ropanicant
  • RateGain's Growth Story Becomes an NYU SPS Case Study
  • Suven Life Sciences Announces Positive Topline Results from Phase-2a Proof-of-Concept Signal Detection Open Label Study of Ropanicant
  • Ahasolar Technologies Ltd receives order worth Rs. 18 lakhs
  • Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast
  • 50% of Indian SMEs prioritize Cloud for business expansion in FY2024, finds 'SME Digital Insights' Study
  • Coforge Named 'Exceptional Performer' in Whitelane Research's 2024 UK IT Sourcing Study
  • Sun Pharma and Moebius Medical Ltd present Phase 2b study on MM-II
  • SPARC announces results from the Planned Interim Analysis of the PROSEEK Study of Vodobatinib in Patients with Early Parkinson's Disease
  • Crompton Built-In Kitchen Appliances recognized as outstanding modern marketing case study
  • Zydus receives approval from USFDA to initiate Phase II clinical trial of ZYIL1 in patients with Parkinson's disease
  • Wockhardt announces successful completion of pivotal Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873
  • LTIMindtree ranks Second in Overall Customer Satisfaction in Whitelane Research's 2023 IT Sourcing Study for Germany
  • JK Tyre secures 'Best-in-Class' ESG grading for second consecutive year
  • TCS Cloud Study: Betting on AI, Global C-Suite Sticking with Cloud, Despite Macro Headwinds
  • Dr. Reddy's successfully completes Phase I study (IV route) of DRL_TC, a proposed biosimilar of tocilizumabp
  • Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada

Latest Post

  • Hero MotoCorp Ltd dispatches 687,220 units in September 2025
  • Synbiotics Ltd's Amphotericin B Manufacturing Facility receives USFDA approval
  • Veefin has successfully integrated CRIF's Strategy One BRE with our no-code Digital Lending Stack
  • Sentynl Therapeutics updates on its NDA for CUTX-101
  • Unimech Aerospace and Manufacturing Ltd experiences slowdown in revenue


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024